Keywords: Gentium, Defibrotide, Veno-occlusive disease, USA, FDA, Sigma Tau

Gentium withdraws US NDA for defibrotide

Article | 19 August 2011

Print This

Italian drug developer Gentium SpA (Nasdaq: GENT) saw its shares price plunge 29% to $6.22 on the Nasdaq after it announced that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in